Inlyta

Thyroid Neoplasms, Pharmacotherapy, Treatment Naive + 2 more
Treatment
4 FDA approvals
13 Active Studies for Inlyta

What is Inlyta

AxitinibThe Generic name of this drug
Treatment SummaryAxitinib is a medication that works to stop the growth of cancer cells by targeting specific receptors on blood vessels that promote the growth of tumors. It is more powerful than other similar drugs and is available in oral form under the brand name Inlyta®. Axitinib works by blocking angiogenesis, which is the process of creating new blood vessels.
Inlytais the brand name
image of different drug pills on a surface
Inlyta Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Inlyta
Axitinib
2012
4

Approved as Treatment by the FDA

Axitinib, commonly known as Inlyta, is approved by the FDA for 4 uses such as Advanced Renal Cell Carcinoma (aRCC) and Kidney Neoplasms .
Advanced Renal Cell Carcinoma (aRCC)
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Avelumab
Kidney Neoplasms
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Avelumab
Pharmacotherapy
Used to treat First Line Chemotherapy in combination with Avelumab
Treatment Naive
Used to treat Treatment Naive in combination with Avelumab

Effectiveness

How Inlyta Affects PatientsAxitinib stops cancer from growing and spreading by preventing new blood vessels from forming in the tumor.
How Inlyta works in the bodyAxitinib stops certain proteins in the body from enabling the growth of new blood vessels.

When to interrupt dosage

The amount of Inlyta is contingent upon the established illness, including Aplastic Anemia, progressed Thyroid malignancy and Aplastic Anemia. The dosage fluctuates as per the method of dispensation specified in the table underneath.
Condition
Dosage
Administration
Thyroid Neoplasms
1.0 mg, , 5.0 mg, 7.0 mg, 3.0 mg
Oral, Tablet, film coated - Oral, Tablet, film coated, , Tablet - Oral, Tablet
Pharmacotherapy
1.0 mg, , 5.0 mg, 7.0 mg, 3.0 mg
Oral, Tablet, film coated - Oral, Tablet, film coated, , Tablet - Oral, Tablet
Treatment Naive
1.0 mg, , 5.0 mg, 7.0 mg, 3.0 mg
Oral, Tablet, film coated - Oral, Tablet, film coated, , Tablet - Oral, Tablet
Kidney Neoplasms
1.0 mg, , 5.0 mg, 7.0 mg, 3.0 mg
Oral, Tablet, film coated - Oral, Tablet, film coated, , Tablet - Oral, Tablet
Disease
1.0 mg, , 5.0 mg, 7.0 mg, 3.0 mg
Oral, Tablet, film coated - Oral, Tablet, film coated, , Tablet - Oral, Tablet

Warnings

There are 20 known major drug interactions with Inlyta.
Common Inlyta Drug Interactions
Drug Name
Risk Level
Description
Bendamustine
Major
The metabolism of Bendamustine can be decreased when combined with Axitinib.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Axitinib.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Axitinib.
Pomalidomide
Major
The metabolism of Pomalidomide can be decreased when combined with Axitinib.
Revefenacin
Major
Axitinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Inlyta Toxicity & Overdose RiskTaking too much axitinib can be dangerous and may cause serious side effects such as high blood pressure, blood clots, bleeding, or a hole in the digestive tract.
image of a doctor in a lab doing drug, clinical research

Inlyta Novel Uses: Which Conditions Have a Clinical Trial Featuring Inlyta?

17 active studies are currently being conducted to determine the efficacy of Inlyta in treating advanced Thyroid Cancer, Aplastic Anemia and other Aplastic Anemias.
Condition
Clinical Trials
Trial Phases
Pharmacotherapy
0 Actively Recruiting
Treatment Naive
0 Actively Recruiting
Thyroid Neoplasms
0 Actively Recruiting
Kidney Neoplasms
13 Actively Recruiting
Not Applicable, Phase 2, Phase 1
Disease
0 Actively Recruiting

Inlyta Reviews: What are patients saying about Inlyta?

5Patient Review
8/23/2012
Inlyta for Cancer Involving the Kidney Cells
I've only been on this medication for a short while, so I'm not sure about its long-term effectiveness yet. The main side effect I've noticed is that my voice has become quite hoarse.
3Patient Review
7/8/2013
Inlyta for Cancer Involving the Kidney Cells
My grandfather takes this medication for his cancer, and while it does seem to be helping, the side effects are sometimes really terrible. He never knows if he's going to wake up with diarrhea or not, and the cough meds only make it worse. He's been on this medication for a year now and he's just so sore all the time from all the coughing.
1Patient Review
6/7/2012
Inlyta for Cancer Involving the Kidney Cells
My husband experienced a severe rupture in his intestinal wall after only 2 weeks on Inlyta. He had to have emergency surgery and is now on hospice care.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about inlyta

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Inlyta a targeted therapy?

"Inlyta is a targeted therapy that specifically targets and binds to the vascular endothelial growth factor receptors (VEGFR) that are located on the inside of cancer cells. VEGFR is a protein that is found on the surface of many normal and cancer cells."

Answered by AI

What are the side effects of the medication Inlyta?

"The following are some of the side effects that may occur: nausea, vomiting, loss of appetite, dizziness, tiredness/weakness, weight loss, temporary hair loss, cough, headache, altered sense of taste, hoarseness, constipation, or upset stomach. If you experience any of these side effects, tell your doctor or pharmacist."

Answered by AI

Is Inlyta chemotherapy?

"Inlyta is not a chemotherapy drug. Chemotherapy drugs work by targeting rapidly growing cells throughout the body, which helps to kill cancer cells. However, this also kills many healthy cells in the body."

Answered by AI

What is Inlyta used for?

"Axitinib is a targeted cancer drug that is also known by its brand name Inlyta. Axitinib is a treatment for advanced kidney cancer. Axitinib might also be used as part of a clinical trial for other types of cancer."

Answered by AI

Clinical Trials for Inlyta

Image of City of Hope Medical Center in Duarte, United States.

RP2 + Tivozanib for Kidney Cancer

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive) after receiving immunotherapy with immune checkpoint inhibitors (ICIs). RP2 is a herpes simplex virus (a viral infection commonly known as the "cold sore virus") that has been changed to infect and destroy tumor cells and to activate (turn on) the human immune system to attack the tumor cells. Tivozanib hydrochloride blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Giving RP2 and tivozanib may be safe, tolerable, and/or effective in treating patients with metastatic renal cell cancer that has progressed after receiving immunotherapy with ICIs.
Phase 2
Waitlist Available
City of Hope Medical Center (+1 Sites)Charles B Nguyen
Image of Columbia University Irving Medical Center in New York, United States.

XL092 + Nivolumab for Kidney Cancer

18+
All Sexes
New York, NY
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
Phase 2
Recruiting
Columbia University Irving Medical Center (+1 Sites)Karie Runcie, MDExelixis
Image of City of Hope Medical Center in Duarte, United States.

CBM588 + Nivolumab + Ipilimumab for Advanced Kidney Cancer

18+
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CBM588 is a live biotherapeutic that may help improve the effects of immunotherapy. Nivolumab and ipilimumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread by enhancing the ability of the body's immune cells to attack tumor cells. CBM588 in combination with nivolumab and ipilimumab may be safe, tolerable, and/or effective in treating patients with advanced stage kidney cancer.
Phase 1
Recruiting
City of Hope Medical CenterAlex Chehrazi-Raffle, MDOsel, Inc.
Image of Mayo Clinic in Florida in Jacksonville, United States.

Nivolumab for Cancer

18+
All Sexes
Jacksonville, FL
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.
Phase 2
Recruiting
Mayo Clinic in FloridaRoxana S. Dronca, M.D.
Have you considered Inlyta clinical trials? We made a collection of clinical trials featuring Inlyta, we think they might fit your search criteria.Go to Trials
Have you considered Inlyta clinical trials? We made a collection of clinical trials featuring Inlyta, we think they might fit your search criteria.Go to Trials
Image of M D Anderson Cancer Center in Houston, United States.

Tumor Treating Fields + Chemotherapy for Cancer

18+
All Sexes
Houston, TX
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the abdomen or thorax that have spread to other parts of the body (advanced). Tumor treating fields therapy on this study utilizes NovoTTF systems that are wearable devices that use electrical fields at different frequencies that may help stop the growth of tumor cells by interrupting cancer cells' ability to divide. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tumor treating fields therapy in combination with either cabozantinib, or with nab-paclitaxel and atezolizumab may help control advanced solid tumors involving the abdomen or thorax.
Phase 1
Recruiting
M D Anderson Cancer CenterApostolia M Tsimberidou
Image of University of California, San Francisco in San Francisco, United States.

Predictive Marker Analysis for Prostate Cancer

18+
Male
San Francisco, CA
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.
Waitlist Available
Has No Placebo
University of California, San FranciscoRahul Aggarwal, MDStrata Oncology
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security